同壁财经讯，企查查数据显示，根据《海南省人民医院2025年先进医疗设备更新项目（一）结果公告 （采购包1）》，上海联影医疗科技股份有限公司于2026年2月26日公告中标海南省人民医院采购项目， 中标金额为7000.00万元。 2025年上半年公司营业收入为60.16亿元，营业收入增长率为12.79%，归属母公司净利润为9.98亿元， 归属母公司净利润增长率为5.03%。 目前公司属于医疗保健行业，主要产品类型为诊断治疗设备，2024年报主营构成为销售医学影像诊断设 备及放射治疗设备:81.99%;提供维修收入:13.16%;其他业务:4.04%;软件收入:0.81%。 同壁财经讯，企查查数据显示，根据《海南省人民医院2025年先进医疗设备更新项目（一）结果公告 （采购包1）》，上海联影医疗科技股份有限公司于2026年2月26日公告中标海南省人民医院采购项目， 中标金额为7000.00万元。 相关上市公司：联影医疗(688271.SH) 同壁财经小贴士： 相关上市公司：联影医疗(688271.SH) 同壁财经小贴士： 联影医疗（688271.SH）2024年营业收入为103.00亿元，营业收入增长率为-9.73 ...

2026 年 02 月 26 日 王睿哲 C0062@capital.com.tw 目标价(元) 153 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | A 股价(2026/2/25) | | 127.45 | | 上证指数(2026/2/25) | | 4147.23 | | 股价 12 个月高/低 | | 164.36/116.93 | | 总发行股数(百万) | | 824.16 | | A 股数(百万) | | 824.16 | | A 市值(亿元) | | 1050.39 | | 主要股东 | | 联影医疗技术集 | | | | 团有限公司 | | | | (20.33%) | | 每股净值(元) | | 26.20 | | 股价/账面净值 | | 4.87 | | 一个月 | | 三个月 一年 | | 股价涨跌(%) | -3.4 | -3.4 -8.5 | | 近期评等 | | | | 日期 | 收盘价 | 评级 | | 2025-10-30 | 146.56 | 买进 | 产品组合 | 销售医学影像诊断设备 | 87.8% | | --- | --- ...

公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | A 股价(2026/2/25) | | 127.45 | | 上证指数(2026/2/25) | | 4147.23 | | 股价 12 个月高/低 | | 164.36/116.93 | | 总发行股数(百万) | | 824.16 | | A 股数(百万) | | 824.16 | | A 市值(亿元) | | 1050.39 | | 主要股东 | | 联影医疗技术集 | | | | 团有限公司 | | | | (20.33%) | | 每股净值(元) | | 26.20 | | 股价/账面净值 | | 4.87 | | 一个月 | | 三个月 一年 | | 股价涨跌(%) | -3.4 | -3.4 -8.5 | | 近期评等 | | | | 日期 | 收盘价 | 评级 | | 2025-10-30 | 146.56 | 买进 | 产品组合 | 销售医学影像诊断设备 | 87.8% | | --- | --- | | 及放射治疗设备 | | | 维保服务 | 9.5% | | 软体业务 | 1.1% | 机构投资 ...

Core Viewpoint - The stock of United Imaging Healthcare has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 11.07%, indicating volatility in investor sentiment and market performance [1]. Financial Performance - For the first half of 2025, United Imaging Healthcare reported a revenue of 6.016 billion yuan, representing a year-on-year growth of 12.79%, and a net profit attributable to shareholders of 998 million yuan, reflecting a growth of 5.03% [2]. - Cumulative cash dividends since the company's A-share listing amount to 641 million yuan [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders decreased by 23.01% to 16,500, while the average number of circulating shares per person increased by 29.89% to 35,953 shares [2]. - Major shareholders include the Huaxia SSE STAR 50 ETF, which increased its holdings by 3.2169 million shares, and the Hong Kong Central Clearing Limited, which raised its stake by 781,970 shares [3]. Stock Performance Metrics - As of October 22, the stock price was 140.16 yuan per share, with a market capitalization of 115.514 billion yuan. The trading volume was 293 million yuan, with a turnover rate of 0.25% [1]. - The stock has seen a decline of 5.44% over the past five trading days and 8.30% over the last 20 days, while it has increased by 5.07% over the past 60 days [1]. Business Overview - United Imaging Healthcare, established on March 21, 2011, specializes in high-performance medical imaging equipment, radiation therapy products, life science instruments, and medical digitalization and intelligence solutions. The main revenue sources include medical imaging diagnostic equipment sales (81.29%), maintenance services (13.56%), and software (0.47%) [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices [1].

Group 1 - The forum held on September 11 aimed to create a high-standard international service trade cooperation platform for the development and investment in China's healthcare industry, focusing on "Natural Protection + AI Governance" [2] - China has become one of the major exporting countries for pharmaceutical investments globally, with investments upgrading to comprehensive cooperation in technology, capital, and standards across various fields [2] - In 2024, China's pharmaceutical innovation authorized transaction volume exceeded $52.26 billion, making it the highest in the world for single transaction amounts and upfront payments, gaining wide recognition in the global pharmaceutical community [2] Group 2 - The "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)" was jointly released by seven government departments, emphasizing that digital transformation is crucial for high-quality development in the pharmaceutical sector [3] - The plan sets two development goals: significant progress in digital transformation by 2027 and comprehensive coverage of digital transformation for large-scale pharmaceutical enterprises by 2030, enhancing innovation capabilities and data systems [4] - Expectations include promoting coordinated development of healthcare product standards, strengthening ethical consensus in AI healthcare, and fostering a collaborative ecosystem for project implementation [4] Group 3 - Experts noted that the integration of natural protection and AI governance is key to breaking through industry challenges, allowing traditional medical wisdom to leverage technology for broader applications [5] - The penetration of AI in the healthcare sector is strong, with active investment and financing in "AI + healthcare," particularly in drug development, medical imaging diagnostics, and smart health management [4][5] - Challenges for the development of "AI + healthcare" include clarifying responsibility in medical accidents, addressing algorithmic bias, and protecting medical data privacy [4]

Group 1 - The core viewpoint of the news is the performance and market position of United Imaging Healthcare, which saw a stock price increase of 5.08% to 149.89 CNY per share, with a total market capitalization of 1235.33 billion CNY [1] - United Imaging Healthcare was established on March 21, 2011, and went public on August 22, 2022. The company specializes in high-performance medical imaging equipment, radiation therapy products, life science instruments, and digital and intelligent medical solutions [1] - The revenue composition of United Imaging Healthcare includes 81.99% from sales of medical imaging diagnostic and radiation therapy equipment, 13.16% from maintenance services, 4.04% from other sources, and 0.81% from software [1] Group 2 - The Qianhai Kaiyuan Fund holds a significant position in United Imaging Healthcare, with its fund, Qianhai Kaiyuan Hong Kong-Shenzhen Leading Selection Mixed A (002443), maintaining 33,400 shares, representing 8.3% of the fund's net value, making it the third-largest holding [2] - The fund has a total scale of 50.21 million CNY and has achieved a year-to-date return of 1.78%, ranking 7614 out of 8248 in its category, while the one-year return is 14.23%, ranking 6337 out of 8051 [2]

Non-Banking Financials - China Ping An (601318.SH) reported a revenue of 500.1 billion and a net profit of 68 billion for H1 2025, with a year-on-year growth of 1.0% and a decline of 8.8% respectively [2][8] - The operating profit after tax (OPAT) increased by 3.7% to 77.7 billion, while the net assets rose by 1.7% to 944 billion [2][8] - The new business value (NBV) for life insurance grew by 39.8%, and the combined ratio (COR) for property insurance improved by 2.6 percentage points to 95.2% [2][8] Pharmaceuticals - Zai Lab (688266.SH) achieved a total revenue of 376 million, marking a 56.07% increase year-on-year, although it reported a net loss of 73 million [13][14] - The company’s key product, Gika Xini, was approved for market, expected to generate significant revenue [14][15] - The pipeline includes promising candidates like ZG005 and ZG006, which are in various stages of clinical trials and have shown strong efficacy [15][16] Utilities and Environmental Protection - China Nuclear Power (601985.SH) reported a revenue of 40.973 billion, a 9.43% increase, but a net profit of 5.67 billion, down 3.66% year-on-year [18][19] - The company plans to distribute a mid-term dividend of 0.02 per share, reflecting its commitment to shareholder returns [20] - The company has 19 units under construction or approved, with a total capacity of approximately 22GW, ensuring long-term growth [20] Medical Devices - Haitai New Light (688677.SH) reported a revenue of 266 million, a 20.50% increase, and a net profit of 74 million, up 5.52% [22][23] - The company’s medical endoscope revenue reached 207 million, with significant growth in overseas markets [23][24] - The gross margin for the company improved to 65.84%, driven by increased sales and operational efficiency [23][24] Construction and Building Materials - Jianghe Group (601886.SH) reported a revenue of 9.339 billion, a decrease of 5.86%, but a net profit increase of 1.69% to 328 million [30][31] - The company has a high dividend payout ratio of 51.82%, indicating strong investor returns [30][31] - The company is expanding its overseas market presence, with significant growth in orders from international markets [31][32] Transportation - Shentong Express (002468.SZ) achieved a revenue of 25.02 billion, a 16.02% increase, but faced a net profit decline of 3.73% [37][38] - The company’s market share reached 12.9%, with a significant volume of 6.54 billion parcels processed [38][39] - The company is focusing on digital transformation and improving customer service to enhance profitability amid competitive pricing pressures [39][40]

Core Insights - The company reported a revenue of 6.016 billion yuan for the first half of 2025, representing a year-on-year increase of 12.79%, with a net profit attributable to shareholders of 999.8 million yuan, up 5.03% [1] - The second quarter of 2025 saw a revenue of 3.538 billion yuan, an increase of 18.60%, and a net profit of 628 million yuan, up 6.99% [1] - The company experienced a steady recovery in domestic demand and accelerated growth in overseas business, with medical imaging and radiation therapy equipment generating 4.890 billion yuan in revenue, a 7.61% increase [1] Revenue Breakdown - By product line, MR revenue reached 1.968 billion yuan (+16.81%), with a significant market share increase, while CT revenue was 1.515 billion yuan (-6.4%) [2] - MI revenue was 841 million yuan (+13.15%), maintaining the top market share in PET/CT for ten consecutive years, and RT revenue was 242 million yuan, with a substantial market share increase of nearly 18 percentage points [2] - Domestic revenue was 4.873 billion yuan (+10.74%), driven by policy implementation and a recovery in market procurement activities, while overseas revenue reached 1.142 billion yuan (+22.48%) [2] Strategic Initiatives - The company's "high-profile" strategy has shown significant results, covering over 70% of U.S. state-level administrative regions and establishing a comprehensive presence in major European economies [3] - The company invested 1.140 billion yuan in R&D in the first half of 2025, accounting for 18.95% of revenue, leading to the launch of over 140 products [3] - The company has achieved comprehensive independent R&D of core components in multiple product lines, ensuring supply chain security and cost advantages [3] Investment Outlook - The company is positioned as a leading domestic medical imaging equipment manufacturer, benefiting from new medical infrastructure policies and large equipment upgrades, with promising overseas market prospects [4] - The forecast for net profit attributable to shareholders for 2025-2027 is adjusted to 2.007 billion yuan, 2.519 billion yuan, and 3.154 billion yuan, reflecting year-on-year growth of 59.05%, 25.51%, and 25.21% respectively [4] - The current stock price corresponds to a PE ratio of 58, 46, and 37 for 2025-2027, maintaining a "recommended" rating [4]

Core Viewpoint - The company reported a decline in revenue and profit for 2024, but showed signs of recovery in Q1 2025, with a focus on both domestic and international market expansion [1][2][3]. Financial Performance - In 2024, the company achieved revenue of 10.3 billion yuan, a decrease of 9.73%, and a net profit of 1.262 billion yuan, down 36.1% [1]. - Q4 2024 revenue was 3.35 billion yuan, down 15.91%, with a net profit of 591 million yuan, down 35.1% [1]. - In Q1 2025, revenue increased to 2.478 billion yuan, up 5.42%, with a net profit of 370 million yuan, up 1.87% [1]. Business Segments - Domestic sales of medical imaging and radiation therapy equipment generated 8.445 billion yuan, a decline of 14.93%, while the service segment grew by 26.81% to 1.356 billion yuan [2]. - International revenue reached 2.266 billion yuan, an increase of 35.08%, accounting for 22% of total revenue, driven by market penetration in high-end segments [2]. R&D and Innovation - The company invested 2.261 billion yuan in R&D in 2024, representing 21.95% of revenue, and 568 million yuan in Q1 2025, accounting for 22.92% of revenue [3]. - The company has achieved significant advancements in technology across various product lines, establishing a competitive edge in the market [3]. Market Strategy - The company is focusing on a dual strategy of high-end product development and comprehensive market penetration domestically, while enhancing localized operations internationally [3]. - The global service network now covers over 85 countries and regions, supporting the operational needs of more than 34,500 devices [3].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% from the current price [2][8]. Core Insights - The company has launched a new stock incentive plan aimed at enhancing growth, targeting a revenue increase of 20%, 44%, and 72.8% for the years 2025 to 2027, respectively, compared to 2024 [8][11]. - The domestic medical equipment market is showing significant recovery, with a 100.36% year-on-year growth in the medical imaging equipment market and a 72.41% growth in the radiation therapy equipment market from January to May 2025 [11]. - The company is expected to achieve net profits of RMB 16.4 billion, RMB 20.0 billion, and RMB 24.2 billion for the years 2025 to 2027, representing year-on-year growth rates of 30.3%, 22.0%, and 20.8%, respectively [11]. Company Overview - The company operates primarily in the medical and biological industry, with a market capitalization of RMB 768.32 billion and a current share price of RMB 129.50 [1]. - The product mix includes 87.8% from medical imaging diagnostic equipment and radiation therapy equipment, 9.5% from maintenance services, and 1.1% from software business [3]. Financial Projections - The company is projected to have a net profit of RMB 1.644 billion in 2025, with an earnings per share (EPS) of RMB 1.99, and a price-to-earnings (P/E) ratio of 64.94 [10][11]. - Revenue is expected to grow from RMB 12.984 billion in 2025 to RMB 18.260 billion by 2027, with corresponding operating profits increasing from RMB 1.733 billion to RMB 2.604 billion [15].